Literature DB >> 26892546

Antibacterials: A sweet vaccine.

David Bundle1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26892546     DOI： 10.1038/nchem.2468

Source DB:  PubMed          Journal:  Nat Chem        ISSN： 1755-4330            Impact factor:   24.427


× No keyword cloud information.
  14 in total

1.  Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidis.

Authors:  Margaret Anne J Gidney; Joyce S Plested; Suzanne Lacelle; Philip A Coull; J Claire Wright; Katherine Makepeace; Jean-Robert Brisson; Andrew D Cox; E Richard Moxon; James C Richards
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

2.  A novel strategy for the synthesis of neoglycoconjugates from deacylated deep rough lipopolysaccharides.

Authors:  Sven Müller-Loennies; Dieter Grimmecke; Lore Brade; Buko Lindner; Paul Kosma; Helmut Brade
Journal:  J Endotoxin Res       Date:  2002

3.  Monoclonal anti-LPS inner core antibodies protect against experimental hematogenous Haemophilus influenzae type b meningitis.

Authors:  S Borrelli; A Diab; A Lindberg; C Svanborg
Journal:  Microb Pathog       Date:  2000-01       Impact factor: 3.738

4.  An antibacterial vaccination strategy based on a glycoconjugate containing the core lipopolysaccharide tetrasaccharide Hep2Kdo2.

Authors:  Lingbing Kong; Balakumar Vijayakrishnan; Michael Kowarik; Jin Park; Alexandra N Zakharova; Larissa Neiwert; Amirreza Faridmoayer; Benjamin G Davis
Journal:  Nat Chem       Date:  2016-02-01       Impact factor: 24.427

5.  Structural basis for selective cross-reactivity in a bactericidal antibody against inner core lipooligosaccharide from Neisseria meningitidis.

Authors:  Matthew J Parker; Kathryn Gomery; Gabrielle Richard; C Roger MacKenzie; Andrew D Cox; James C Richards; Stephen V Evans
Journal:  Glycobiology       Date:  2014-01-31       Impact factor: 4.313

6.  Antigenic potential of a highly conserved Neisseria meningitidis lipopolysaccharide inner core structure defined by chemical synthesis.

Authors:  Anika Reinhardt; You Yang; Heike Claus; Claney L Pereira; Andrew D Cox; Ulrich Vogel; Chakkumkal Anish; Peter H Seeberger
Journal:  Chem Biol       Date:  2015-01-15

7.  Diversity-oriented synthesis of inner core oligosaccharides of the lipopolysaccharide of pathogenic Gram-negative bacteria.

Authors:  You Yang; Shunsuke Oishi; Christopher E Martin; Peter H Seeberger
Journal:  J Am Chem Soc       Date:  2013-04-10       Impact factor: 15.419

8.  Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia.

Authors:  Joyce S Plested; Shannon L Harris; J Claire Wright; Philip A Coull; Katherine Makepeace; Margaret-Anne J Gidney; Jean-Robert Brisson; James C Richards; Dan M Granoff; E Richard Moxon
Journal:  J Infect Dis       Date:  2003-04-02       Impact factor: 5.226

Review 9.  Neutralizing and cross-reactive antibodies against enterobacterial lipopolysaccharide.

Authors:  Sven Müller-Loennies; Lore Brade; Helmut Brade
Journal:  Int J Med Microbiol       Date:  2007-06-01       Impact factor: 3.473

10.  Naturally-occurring human serum antibodies to inner core lipopolysaccharide epitopes of Neisseria meningitidis protect against invasive meningococcal disease caused by isolates displaying homologous inner core structures.

Authors:  Anne Jäkel; Joyce S Plested; J Claire Hoe; Katherine Makepeace; Margaret-Anne J Gidney; Suzanne Lacelle; Frank St Michael; Andrew D Cox; James C Richards; E Richard Moxon
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641
View more
  2 in total

1.  Correction.

Authors: 
Journal:  Nat Chem       Date:  2016-10-21       Impact factor: 24.427

Review 2.  E. coli Group 1 Capsular Polysaccharide Exportation Nanomachinary as a Plausible Antivirulence Target in the Perspective of Emerging Antimicrobial Resistance.

Authors:  Shivangi Sachdeva; Raghuvamsi V Palur; Karpagam U Sudhakar; Thenmalarchelvi Rathinavelan
Journal:  Front Microbiol       Date:  2017-01-31       Impact factor: 5.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.